<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04492774</url>
  </required_header>
  <id_info>
    <org_study_id>SMC2020002</org_study_id>
    <nct_id>NCT04492774</nct_id>
  </id_info>
  <brief_title>Degenerative Lumbar Stenosis Conservative Treatment</brief_title>
  <acronym>GOLDSTEN</acronym>
  <official_title>GOLDIC Therapy in Lumbar Degenerative Spinal Stenosis - Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutherland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutherland Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial aims to compare the effectiveness of three methods of conservative treatment of&#xD;
      degenerative lumbar spine stenosis (DLSS): GOLDIC autologous serum epidural injections,&#xD;
      steroid epidural injections and manual therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Degenerative Lumbar Spinal Stenosis (DLSS) is a serious health problem for&#xD;
      patients over 65 years of age. It is assumed that in the United States alone, it affects&#xD;
      about 200 thousand patients causing significant impairment of their quality of life. Although&#xD;
      it is relatively easy to confirm the nature of spinal canal encroaching (disc protrusion,&#xD;
      facet hypertrophy, ligamentous folding) by several methods of imaging, the golden standard of&#xD;
      DLSS management, especially in the group of older patients, is still the matter of debate.&#xD;
      Three main concepts of conservative treatment are considered: 1) pharmacological care -&#xD;
      symptom-oriented systemic anty-inflammatory and analgesic agents or local steroid injections,&#xD;
      2) rehabilitations protocols and mechanical devices like traction facilities or corsets to&#xD;
      decompress spinal canal or support in case of instability, 3) biological - stimulation of&#xD;
      anti-inflammatory action and regeneration capacity by biologically active substances. All&#xD;
      methods are offered without strong evidence of its efficacy.&#xD;
&#xD;
      AIM: Comparison of the effectiveness of three treatment protocols in DLSS: epidural&#xD;
      injections of autologous serum (Gold Induced Cytokines, Goldic), epidural steroid injections,&#xD;
      manual therapy in the concept of spinal canal venous drainage.&#xD;
&#xD;
      Research hypothesis: The use of Goldic serum in epidural injections improves the condition of&#xD;
      patients with DLSS during the observation period longer than steroid injections and the&#xD;
      rehabilitation protocol.&#xD;
&#xD;
      DESIGN: Randomized prospective trial without blinding. SETTING: Open study for outpatients,&#xD;
      single-centre study. POPULATION: the local adult population METHODS: Three groups of patients&#xD;
      (A, B, C) with confirmed DLSS in MRI, without limiting sex, age, meeting health conditions&#xD;
      according to the inclusion and exclusion criteria. There will be 30 people in each group (90&#xD;
      people in total).&#xD;
&#xD;
      Group A - Goldic serum therapy - 4 injections at 3-day intervals containing single doses of&#xD;
      serum (4 doses of 3 ml in total), injections performed into the epidural space under&#xD;
      ultrasound control by the same operator.&#xD;
&#xD;
      Group B - steroid therapy with Dexaven 4 mg / 1 ml - 2 injections at weekly intervals&#xD;
      containing single doses of dexamethasone (total dose of 8 mg), injections will be performed&#xD;
      into the epidural space under ultrasound control by the same operator.&#xD;
&#xD;
      Group C - manual therapy according to the concept of venous drainage - a repeatable treatment&#xD;
      scheme for each patient; decompression of the thoracic outlet, diaphragm release, sacroiliac&#xD;
      joints (SI) mobilizations, rib-sternum release, rib raising technique - 4 sessions (1 x&#xD;
      weekly - approx. 40 min).&#xD;
&#xD;
      Control tools: NRS Pain Scale (0-10), Oswestry Disability Index, Zurich Claudication&#xD;
      Questionnaire (ZCQ), EQ-5D-5L, Control points: Initial Assessment (IA), 4,12, 24 weeks after&#xD;
      last intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EQ-5D-5L index from baseline to 24 weeks</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oswestry Disability Index from baseline to 24 weeks</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 24 weeks</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pain intensity according to Numeric Rating Scale</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain intensity according to Numeric Rating Scale</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain intensity according to Numeric Rating Scale</measure>
    <time_frame>Change from baseline to 24 weeks</time_frame>
    <description>Generic outcome measure. Range: 0 (no pain) - 10 (the worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D-5L index from baseline to 4 weeks</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D-5L index from baseline to 12 weeks</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>EQ-5D-5L index estimated from EQ-5D-5L desrcriptive system based on Polish directly measured value set. Mininmum: -0.590; Maximum: 1.0; More points means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oswestry Disability Index from baseline to 4 weeks</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oswestry Disability Index from baseline to 12 weeks</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 0 (the best score) - 50 (the worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 4 weeks</measure>
    <time_frame>Change from baseline to 4 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Zurich Claudication Questionnaire (ZCQ) from baseline to 12 weeks</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Disease-specific questionnaire. Range: 12 (the best score) - 55 (the worst score).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Spinal Stenosis Lumbar</condition>
  <condition>Spinal Canal Stenosis</condition>
  <arm_group>
    <arm_group_label>GOLDIC serum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidural ultrasound guided injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epidural ultrasound guided injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>veno-lymphatic spinal drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Goldic serum</intervention_name>
    <description>epidural injections</description>
    <arm_group_label>GOLDIC serum</arm_group_label>
    <other_name>Autologous serum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid injections</intervention_name>
    <description>epidural injections</description>
    <arm_group_label>Steroid</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Manual therapy</intervention_name>
    <description>Veno-lymphatic drainage</description>
    <arm_group_label>Manual therapy</arm_group_label>
    <other_name>drainage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical signs of lumbar spinal stenosis&#xD;
&#xD;
          2. Radiological signs of lumbar spinal stenosis confirmed by MRI&#xD;
&#xD;
          3. No contraindications to steroid therapy or spinal epidural injections (glaucoma, high&#xD;
             RR values, diabetes, anticoagulants, active infections, etc.)&#xD;
&#xD;
          4. Mental state allowing cooperation during manual therapy&#xD;
&#xD;
          5. An adult who consents to participate in the study&#xD;
&#xD;
          6. No previous surgery or spinal epidural injections&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of serious neurological deficits&#xD;
&#xD;
          2. Stenosis of other origin - post-traumatic, spondylolisthesis, cancer, infection&#xD;
&#xD;
          3. Contraindications to steroid therapy or spinal injections (glaucoma, high RR values,&#xD;
             diabetes, anticoagulants, active infections, etc.)&#xD;
&#xD;
          4. Previous surgery or spinal epidural injections of lumbar spine&#xD;
&#xD;
          5. Mental state preventing cooperation during manual therapy&#xD;
&#xD;
          6. Lack of consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Godek, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutherland Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sutherland Medical Center</name>
      <address>
        <city>Warszawa</city>
        <state>Mazovia</state>
        <zip>04-036</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sutherland Medical Center</investigator_affiliation>
    <investigator_full_name>Piotr Godek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

